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Abstract 
Cancer patients can suffer oral toxic effects secondary to antineoplastic therapy in the form of radiotherapy and/
or chemotherapy. This risk is conditioned by a range of factors, including the high cell turnover rate of the oral 
mucosa, the diversity and complexity of the oral microflora, and soft tissue trauma during normal oral function. The 
present study offers a literature review of the main oral complications secondary to chemotherapy, and describes 
the different options for dental treatment before, during and after oncological treatment, published in the scientific 
literature. To this effect a PubMed-Medline® search was made using the following keywords: chemotherapy, can-
cer therapy, dental management, oral mucositis, neurotoxicity, intravenous bisphosphonates and jaw osteonecrosis. 
The search was limited to human studies published in the last 10 years in English or Spanish. A total of 50 articles 
were identified: 17 research papers, 25 reviews, 6 letters to the Editor, and two clinical guides developed by expert 
committees. The data obtained showed the main oral complications of chemotherapy to be mucositis, neurotoxici-
ty, susceptibility to infections, dental, salivary and taste alterations, and the development of osteonecrosis. Based 
on the reviewed literature, elective dental treatment can be provided before chemotherapy, with emphasis on the 
elimination of infectious foci. During chemotherapy, dental treatment should be limited to emergency procedures, 
while dental treatment of any kind can be prescribed after chemotherapy – with special considerations in the case 
of patients who have received treatment with intravenous bisphosphonates.
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intravenous bisphosphonates.
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Introduction
Anticancer chemotherapy currently involves the use of 
drugs (cytostatic or cytotoxic agents) that avoid prolife-
ration of the tumor cells and/or cause their destruction, 
taking advantage of the characteristically shortened cell 
cycle of these cells. The main problem posed by such 
treatment is the lack of selectivity of most antineoplastic 
drug substances, since they also act upon normal cells 
with an accelerated cell cycle, such as bone marrow 
cells, hair follicle cells and the epithelial cells of the 
gastrointestinal tract (1). The chemotherapeutic agents 
most commonly used in head and neck malignancies are 
bleomycin, cisplatin, methotrexate, 5-fluorouracil, vin-
blastine and cyclophosphamide (2).
Etiopathogenesis: cytostatic drug toxicity
Antineoplastic drugs can act upon the different tissues ei-
ther directly or indirectly. The direct side effects of such 
drugs start with the primary oral tissue damage caused 
by their indiscriminate effect upon the cell replication 
cycle, such as for example in the oral mucosa, where 
these cytotoxic agents destroy the proliferating basal 
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cells of the mucosal layer. Replacement or turnover of 
the cells lost and desquamated in the more superficial 
layers of the mucosa is thus adversely affected, resul-
ting in mucosal ulceration (1). The indirect side effects 
in turn are caused by non-oral actions that have a colla-
teral impact upon the oral cavity, such as bone marrow 
suppression, the loss of tissue immune cells, and the loss 
of salivary protective elements. 
General side effects of chemotherapy
Some of the most frequent side effects of chemotherapy 
are bone marrow suppression, resulting in leukopenia 
(observable in peripheral blood towards day 10 after the 
start of chemotherapy), thrombocytopenia (after 10-14 
days) and anemia (less frequent and slower in develo-
ping). Other common effects are nausea and vomiting, 
hair loss (alopecia), and hand-foot syndrome (clinically 
characterized by painful, symmetrical erythema of the 
palms and soles, often preceded by paresthesias in the 
affected zones)(3,4). Most of the side effects gradually 
disappear after the end of treatment, though in some 
cases permanent damage may be observed at cardiac 
(myocardiopathy), pulmonary (fibrosis), renal (chronic 
renal failure) or reproductive level (sterility).
Material and methods
The present study offers a literature review of the main 
oral complications secondary to chemotherapy, and des-
cribes the different options for dental treatment before, 
during and after oncological treatment, published in the 
scientific literature. To this effect a PubMed-Medline® 
search was made using the following keywords: chemo-
therapy, cancer therapy, dental management, oral mu-
cositis, neurotoxicity, intravenous bisphosphonates and 
jaw osteonecrosis. The search was limited to human stu-
dies published in the last 10 years in English or Spanish. 
The titles and summaries / abstracts of the identified ar-
ticles were analyzed, with the selection of a total of 48 
publications. After compiling the information on each of 
them, two additional articles were added, in view of their 
relevance: one predating the mentioned 10-year period, 
and the other not indexed in the database. A total of 50 
articles were thus evaluated: 17 research papers (4 clini-
cal trials, 2 cohort studies, 2 case-control publications, 8 
case series, and one cross-sectional study), 25 reviews, 
6 letters to the Editor, and two clinical guides developed 
by expert committees (Table 1).
Results
1. Oral side effects of chemotherapy
The most common oral complications observed after 
chemotherapy are mucositis, infections, neurological 
and dental alterations, dysgeusia, hyposialia and xeros-
tomia (dry mouth), bleeding tendency, and the develo-
pment of osteonecrosis. The soft tissues of the lips, the 
oral mucosa, tongue, soft palate and the pharyngeal mu-
cosa are the most affected areas.
Mucositis
Mucositis is an inflammatory reaction of the mucosal 
membranes secondary to antineoplastic treatments such 
as radiotherapy (in 80% of the cases) and chemotherapy 
as treatment for solid tumors or lymphomas (in approxi-
mately 40-50%, particularly with the cytostatic agent 
5-fluorouracil) or as conditioning treatment for bone ma-
rrow transplantation (in over 75% of the patients)(5-7). 
Mucositis is regarded as a manifestation of leukopenia.
The mechanism by which mucositis develops is not 
clear, though it is generally attributed to the fact that the 
oral mucosal cells have a relatively high mitotic rate, 
thereby establishing them as targets of the action of 
cytostatic agents (5,8,9). Diseases such as diabetes and 
cardiovascular disorders have been described as possi-
ble risk factors, though no direct relationship has been 
found (10). According to Logan et al. (2007), there are 
5 stages in the clinical mucosal changes that give rise to 
mucositis: initiation; over-regulation and the production 
of mediators; signaling and amplification; ulceration; 
and healing (Fig. 1)(9). This hypothesis underscores the 
role of transcription factors and proinflammatory cytoki-
nes in the development of mucositis (9).
Mucositis usually appears 4-7 days after the start of high-
dose chemotherapy, and is of a self-limiting nature (pro-
vided overinfection does not occur). It in turn disappears 
2-4 weeks after the conclusion of cytotoxic chemothe-
rapy (11). The drugs most often associated with the 
development of mucositis are doxorubicin, bleomycin, 
fluorouracil and methotrexate (12). Clinically, the con-
dition manifests as erythema, edema or ulceration, with 
severe pain, bleeding and potential side effects such as 
xerostomia, the risk of both local (overinfection due to 
Candida) and systemic infection, malnutrition, fatigue, 
dental caries and gastrointestinal disorders over time 
(5). Because of these complications, in some cases the 
patient may require parenteral nutrition and even potent 
analgesics, administered in the hospital setting (8,9,12). 
Different methods have been developed for measuring 
and quantifying the changes occurring in the oral mu-
cosa, including general scales, multiple-variable scales 
and treatment specific scales (8). The currently most 
widely used scale is that of the World Health Organi-
zation (WHO), based on the identification of erythema 
at exploration and the degree of patient discomfort or 
pain (5).
Regarding the prevention and treatment of mucositis, 
studies have been made with different agents (sucralfate, 
chlorhexidine, povidone iodine, doxepin, benzidamine, 
cryotherapy, low-energy laser, etc.), though none have 
been shown to prevent the disorder (6,13). Donelly et al. 
(2003) carried out a systematic review in which 42% of 
the published studies (13 articles) reported that the ad-
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ministration of antimicrobial agents offers some benefit 
in relation to the symptoms of mucositis (14). Howe-
ver, Clarkson et al. (2004), in a Cochrane review of 27 
publications, found that among 8 prophylactic agents 
used to obtain relief from mucositis, crushed ice yiel-
ded the best results (15). Posteriorly, Keefe et al. (2007) 
published an update on the clinical guides for the pre-
vention and treatment of oral and gastrointestinal mu-
cositis (16). The currently most widely used treatment 
is the use of 2% lidocaine rinses in combination with 
0.12-0.2% chlorhexidine during 30 seconds, every three 
or four hours. Colella et al. (2010) have suggested that 
the frequent application of a spray consisting of synthe-
tic collagen precursor amino acids in combination with 
sodium hyaluronate can offer rapid and effective pain re-
lief, and contributes to mucosal healing – though further 
randomized and controlled studies are needed to more 
firmly establish its usefulness (17).
Oral infections
Dental treatment prior to the start of cytoreductive the-
rapy substantially reduces the risk of severe infections 
(1,5). The main infectious processes are the following:
1. Bacterial infections: These are usually caused by 
gramnegative organisms. Signs of inflammation may 
be masked as a result of the underlying bone marrow 
suppression; consequently, oral hygiene protocols that 
reduce microbial colonization of the dentition and perio-
dontium are important during the period of bone marrow 
suppression. During oncological treatment, and particu-
larly in patients with advanced-stage malignancies, it is 
common to observe poorer oral hygiene, and thus an in-
creased presence of dental plaque (18). In the study pu-
blished by López-Galindo et al. (2006), increased dental 
plaque was observed, along with more caried and mis-
Fig.1. Diagram illustrating mucosal and clinical changes that occur leading to mucositis according to the current hypothesis. The five over-
lapping stages are demonstrated (1) initiation; (2) upregulation and message generation; (3) signalling and amplification; (4) ulceration; (5) 
healing. Figure belongs to article made by Logan et al. (9).
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sing teeth, among oncological patients prior to treatment 
- though the modified periodontal index was similar in 
both the oncological patients and controls (1). Patients 
with previous dental and periodontal diseases eliminated 
before the start of oncological therapy and subjected to 
intensive dental care during therapy show a significant 
reduction in the frequency of oral complications associa-
ted to chemotherapy (1,19). Teeth with an unfavorable 
prognosis should be removed at least 10 days before the 
start of chemotherapy (20).
2. Fungal infections: Bone marrow suppression, oral 
mucosal lesions and salivary alterations contribute to the 
development of Candida albicans infection (18). The 
most common presentations are pseudomembranous 
candidiasis, followed by erythematous candidiasis. The 
treatment of these conditions involves the use of topical 
and/or systemic antifungal agents (Table 2) complemen-
ted with an antiseptic (chlorhexidine). The latter should 
be used at least 30 minutes before or after nystatin, since 
the combination of both may prove ineffective. In the 
case of more severe infections, the recommendation is a 
systemic antifungal such as fluconazole or ketoconazole. 
The efficacy of such treatment is limited, and resistances 
may appear. In such cases intravenous amphotericin B 
or itraconazole via the oral route at a dose of 200-400 
mg/day tend to be the drugs of choice.
3. Viral infections: In most cases, infections due to her-
pes simplex virus (HSV), varicella-zoster virus (VZV) 
and Epstein-Barr virus (EBV) are the result of the reac-
tivation of a latent virus, while infections due to cytome-
galovirus (CMV) can result from the reactivation of a 
latent virus or from a recently acquired virus (20).
Infection due to HSV: The severity of the lesions increa-
ses drastically with the degree of immune suppression. 
The HSV lesions are more diffuse but less painful than 
those associated with radiotherapy. Moreover, recurrent 
intraoral HSV infection may present ulcerations of mu-
cosal areas not adhered to periosteum (i.e., soft palate 
and tongue)(20). The incidence of oral lesions due to 
recurrent HSV infections in bone marrow-suppressed 
cancer patients has decreased considerably following 
the introduction of prophylactic aciclovir at a dose of 
800 mg/day, beginning on day four after the start of 
chemotherapy. In patients without antiviral prophylaxis, 
the oral lesions generally appear simultaneously with 
chemotherapy or chemo-radiotherapy during the period 
of most intense immune suppression. The treatment of 
HSV infection consists of the administration of 400-800 
mg of aciclovir via the oral route 5 times a day or of 5-10 
mg/kg via the intravenous route every 8-12 hours, for as 
long as the lesions persist.
Infection due to VZV: Immune compromised patients 
may present involvement of several dermatomes, or 
alternatively the lesions may show a more generalized 
Table 2. Treatment of oral candidiasis and infection due to VZV in the chemotherapy patient.
ORAL 
CANDIDIASIS
TYPE OF 
ADMINIS-
TRATION
DRUG NAME DOSE DOSAGE DURATION
Topical
Nystatin Mycostatin®
100.000 
I.U./cc
rinses
4-6 times/day 30 days
Miconazole Daktarin
® gel
Fungisdin® gel
100 mg 
gel 4 times/day 30 days
Systemic
Fluconazole Diflucan® 150 mg orally 1 time/day 3 weeks
Ketoconazole
Fungarest®
Ketoisdin®
Panfungol®
200-
400 mg 
orally
1 time/day 3 weeks
Itraconazole
Canadiol®
Hongoseril®
Spranox®
200-
400 mg 
orally
1 time/day 30 days
Intravenous AmphotericinB Ambisome® 0,4-0,6 mg/kg 1 time/day 30 days
VZV
SEVERE IMMUNE 
COMPROMISED
LESS SEVERE IMMUNE 
COMPROMISED RESISTANCES
- Aciclovir intravenously 5-10 
mg/Kg 3 times/day during 5 days.
- Aciclovir 800mg orally/ 5 times 
per day/ 5-7 days.
- Famciclovir 500mg orally/ 3 times 
per day/ 7 days.
- Valaciclovir 1000mg orally/ 3 
times per day/ 7 days.
- Foscarnet intravenously 
40mg/kg/3 times per day.
VZV: varicella-zoster virus; I.U.: international units; cc: cubic centimeter.
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distribution, generally manifesting several weeks after 
the interruption of chemotherapy – in contrast to the 
situation with HSV. A number of antiviral agents are 
used as treatment, depending on the degree of immune 
suppression of the patient and the resistances to these 
drugs (Table 2).
Infection due to CMV and EBV: Lesions produced by 
CMV are characterized by the presence of multiple mild 
or moderate ulcerations with irregular margins. The ini-
tial lesions appear during the first periods of bone ma-
rrow regeneration and are characterized by nonspecific 
pseudomembranous ulcers covered by a fibrin exudate 
with a granulomatous base. At present, ganciclovir is the 
treatment of choice for acute CMV infection. The risk 
of EBV infection usually manifests months after the in-
terruption of myeloablative therapy used for transplant 
conditioning.
Neurotoxicity
A number of chemotherapeutic agents such as vincristi-
ne and vinblastine are able to cause direct neurotoxicity. 
Patients may experience deep and palpitating mandibu-
lar pain that tends to subside one week after concluding 
chemotherapy. A correct anamnesis is required, together 
with oral exploration and an X-ray study in order to dis-
tinguish such pain from pain of pulp origin. In some ca-
ses, dental hypersensitivity may appear weeks or months 
after the end of chemotherapy; in these cases, the topical 
application of fluoride or the use of a desensitizing too-
thpaste may help lessen the symptoms. 
Dysgeusia
During chemotherapy, patients may experience an un-
pleasant metallic taste due to diffusion of the chemo-
therapeutic agent into the oral cavity. Dysgeusia as such 
initially manifests a few weeks after starting cytotoxic 
treatment, and is generally reversible within a few wee-
ks. The CMF (cyclophosphamide, methotrexate and 
5-fluorouracil) and CEF protocol agents (cyclophospha-
mide, epirubicin and 5-fluorouracil), and their derivati-
ves, can be detected in saliva for days after the infusion 
(18). Dysgeusia is an important symptoms in these pa-
tients, since apart from the direct neurotoxic effect upon 
the gustatory cells, it is reinforced by other factors such 
as xerostomia, infections, and the psychological condi-
tions of the patient (21).
Hyposialia and xerostomia
Hyposialia, attributable to the effect of chemotherapy 
upon the cells of the salivary glands, is transient and 
reversible. It appears particularly with the use of adria-
mycin, and can cause oral functional problems, espe-
cially in relation to speech and mastication. These pa-
tients show alterations in the salivary components, with 
an increase in the levels of peroxidase and amylase, a 
reduction in total secreted immunoglobulins A and G, 
and the presence of the chemotherapeutic drug itself. All 
these factors favor the development of mucositis (21). 
As a result, patients should drink abundant water and use 
sugar-free sweets or chewing gum to increase salivation. 
In more moderate cases, sialogogues such as pilocarpi-
ne, bromhexine or bethanechol can be used.
Alterations in dental growth and development
Unlike radiotherapy, which only affects the cells within 
the irradiated zone, chemotherapy has a systemic effect. 
As a result, the developing odontogenic cells are sus-
ceptible to chemotherapy, even when far removed from 
the tumor site. Minicucci et al. (2003) detected delays 
in dental development, hypoplasia and microdontia in 
children receiving chemotherapy (22).
Bleeding tendency
Bleeding is due to alterations resulting from throm-
bocytopenia (in turn a consequence of bone marrow 
aplasia). Clinically, patients my present petechiae, ec-
chymosis, hematomas or diffuse bleeding. Rinses with 
0.12% chlorhexidine avoid overinfection and can help 
eliminate the traces of blood, though caution is requi-
red in order not to alter the clots, since this could lead 
to further bleeding. In the presence of platelet counts of 
under 50,000/mm3, tooth extractions or dental surgery 
should not be performed, while counts of under 20,000 
platelets/mm3 are associated with spontaneous bleeding 
– particularly in patients with previous gingivitis. The 
treatments of choice in the event of bleeding comprise 
the use of vasoconstrictors such as topical epinephrine, 
mucoadherent tissue protectors such as the cyanoacryla-
tes (which seal the bleeding sites and protect the formed 
clots), and procoagulating agents such as topical throm-
bin or hemostatic collagen, which organize and stabilize 
the blood clots. The risk of infection or bleeding in these 
patients persists for the duration of the effect of the cyto-
toxic drugs administered in each chemotherapy session.
Osteonecrosis
Osteonecrosis of the jaw (ONJ) is observed in patients 
treated with bisphosphonates (BPs). These drugs inhibit 
bone resorption and are administered via the intravenous 
route as treatment in application to bone metastases in 
cancer patients, in malignant hypercalcemia (tumor-
induced hypercalcemia), or in patients with multiple 
myeloma – affording improved survival and quality of 
life (23). Although much less commonly, ONJ has also 
been observed in patients receiving treatment with oral 
bisphosphonates (used for the prevention and treatment 
of osteoporosis and in certain bone conditions such as 
Paget’s disease). The intravenous BPs most associated 
with ONJ are zoledronic acid (Zometa®) and pamidro-
nate (Aredia®).
The precise incidence of ONJ in cancer patients is not 
known, since the figures differ according to the literature 
source (0.8%-12%)(24-26). Recent studies such as those 
published by Bagán et al. (2009) suggest an incidence 
of 1-3% among oncological patients receiving treatment 
with intravenous bisphosphonates (27). Although these 
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estimations point to a low percentage of ONJ, an increa-
sing number of cases are being detected, and the figu-
res can be expected to continue to increase in the future 
(23,27). ONJ tends to appear after invasive dental ma-
nipulation, particularly after tooth extraction – the latter 
being the most important triggering factor in the deve-
lopment of ONJ (23,24,26-30). Habits such as smoking 
and alcohol consumption have been more closely related 
to the development of osteoradionecrosis (ORN) than 
to ONJ. In the study published by Bagán et al. (2009), 
22.6% of the patients who developed ONJ were smokers, 
versus 60% of the patients with ORN (29).
In 2008, a national expert committee with the repre-
sentation of maxillofacial surgeons, stomatologists and 
odontologists, established a series of recommendations 
on how to conduct oral revisions, defining those dental 
treatments that should be carried out before and during 
treatment with intravenous bisphosphonates (23). The 
diagnostic criteria for ONJ established by these experts 
were: patients receiving or having received treatment 
with BPs; the presence of one or more ulcerated mu-
cosal lesion of the alveolar processes, with or without 
the exposure of maxillary or mandibular bone; exposed 
bone presenting a necrotic appearance; lesions presen-
ting spontaneously or after dentoalveolar surgery (par-
ticularly extractions); and the absence of healing over a 
period of at least 6 weeks.
Clinically, ONJ is typically characterized by pain (pro-
gressive and sustained, and sometimes requiring impor-
tant analgesic doses to secure control – the patient being 
asymptomatic in the early stages)(30-33). In order to 
establish and plan the treatment of ONJ, Bagán et al. 
(2009) proposed a modification of the staging classifi-
cation used up to that time (30). Table 3 describes the 
different clinical stages and corresponding treatments.
Although the clinical manifestations are usually suffi-
cient to establish the diagnosis, in those cases where do-
ubts exist regarding the differential diagnosis between 
ONJ and bone metastasis, a biopsy is advisable. Other 
complementary diagnostic tests are culture of the ex-
posed zone and definition of the corresponding antibio-
gram, together with a panoramic X-ray and computed 
tomography study (27). Another technique subject to 
discussion is the evaluation of the serum concentrations 
of CTX (collagen fragments that are freed during bone 
remodeling and turnover), since BPs reduce these con-
centrations. It is therefore believed that CTX determina-
tion may be a reliable risk marker, though a number of 
studies have found no statistically significant relations-
hip between the serum levels of CTX and the number 
of areas of exposed necrotic bone or magnitude of ONJ 
(27,34).
Since the treatment of ONJ is often unsatisfactory, ma-
nagement should aim to afford pain relief, control soft 
tissue and bone infection, and avoid or reduce the pro-
gression of bone necrosis (28,35).
2. Dental treatment before, during and after chemothe-
rapy
All oncological patients should visit the dentist before 
receiving radiotherapy, chemotherapy or both, since the 
severity of the oral complications can be significantly 
reduced if a prior intensive strategy is applied to secure 
stabilized oral hygiene.
Treatment before chemotherapy
Before chemotherapy, the dentist should consult the on-
cologist to determine the current condition of the patient 
Table 3. Staging classification and treatment of osteonecrosis of the jaws by bisphosphonates. In the case of normal 
flora for 15 days, it is recommended the use of amoxicillin/clavunate, doxycicline or azytromycin as antibiotic of 
choice.
STAGING 
CLASSIFICATION
CLINICAL MANIFESTATIONS TREATMENT
STAGE 1
Exposed bone necrosis or small oral 
ulceration without exposed bone necrosis, 
but without symptoms.
Rinses with 0.12% 
chlorhexidine and checkup.
STAGE 2A
Exposed bone necrosis or a small oral fistula 
without exposed bone necrosis, but with
Symptoms controlled with medical 
treatment.
Rinses with 0.12% 
chlorhexidine, antibiotic, 
analgesics and checkup.
STAGE 2B
Exposed bone necrosis or a small oral 
fistula without exposed bone necrosis, but 
with symptoms not controlled with medical 
treatment.
Rinses with 0.12% 
chlorhexidine, antibiotic, 
analgesics and surgery with 
removal of the zone of bone 
necrosis.
STAGE 3 Jaw fractures, skin fistula, osteolysis extending to the inferior border.
Rinses with 0.12% 
chlorhexidine, antibiotic, 
analgesics and extensive 
surgery with resection of 
bone.
e39
J Clin Exp Dent. 2011;3(1):e31-42.                                                                      Dental treatment in chemotherapy.
and the type of treatment planned (Table 4). In addition, 
an exhaustive examination of the oral cavity is required, 
together with a radiological study (intraoral – periapical 
and bitewing – and panoramic) in order to discard peria-
pical lesions and/or bone alterations, and the evaluation 
of periodontal health.
Denture fitting is to be checked, with readjustment or 
removal of those prostheses that prove traumatic, and 
all infectious foci are to be eliminated (caries, fillings in 
poor condition).
Dental fluorization is indicated, as well as rinses with 
0.12% chlorhexidine and general prophylactic measu-
res. In children, sealing of cracks and fissures in recently 
erupted molars and premolars is advised. Adequate oral 
health conditions should be sought before chemotherapy 
is applied, since the negative effects of the latter are more 
limited when the oral cavity is healthy than when there 
are pre-existing dental or periodontal problems (1,2).
Teeth that are non-viable or present a poor prognosis 
(pericoronitis, extensive caries, advanced periodontal 
disease and periapical disorders) should be removed at 
least two weeks before, while major surgical procedures 
should be carried out 4-6 weeks before chemotherapy. 
The patient should be informed of the complications of 
treatment (e.g., mucositis).
If the patient is to receive treatment with intravenous 
BPs
In patients programmed to receive intravenous BPs, the 
above described measures are likewise applicable, and 
moreover the dentist should inform the oncologist of 
Table 4. Dental treatment before, during and after chemotherapy.
TREATMENT BEFORE 
CHEMOTHERAPY
TREATMENT DURING 
CHEMOTHERAPY
TREATMENT AFTER 
CHEMOTHERAPY
The dentist should consult the −	
oncologist to determine the current 
condition of the patient and the type 
of treatment planned.
The oncologist should be consulted in −	
order to know the degree of immune 
suppression of the patient.
The dentist should consult the −	
oncologist to determine immune 
competence.
Exhaustive examination of the oral −	
cavity: discard periapical lesions 
and/or bone alterations, and the 
evaluation of periodontal health.
Denture fitting should be checked, −	
with readjustment or removal 
of those prostheses that prove 
traumatic.
Radiological study: intraoral −	
(periapical and bitewing) and 
panoramic.
Treatment of the complications −	
of chemotherapy (mucositis, 
xerostomia…).
Insist on the need for routine −	
systematic oral hygiene.
Use of chlorhexidine rinses and −	
fluorization.
General prophylactic measures: tartar −	
removal, dental fluorization and 
rinses with 0.12% chlorhexidine.
Continued patient reminder of the −	
need to maintain strict dental hygiene 
is indicated, with the added use of 
chlorhexidine rinses and fluorization.
The patient should be informed of −	
the complications of treatment.
Analgesics: paracetamol/metamizol.−	
NO NSAID.−	
Antibiotics: dose adjustment is −	
required according to the observed 
creatinine clearance values in patients 
with kidney problems.
Teeth that are non-viable or present a −	
poor prognosis should be removed:
Minor surgery: al least two weeks o 
before chemotherapy.
Major surgery: 4-6 weeks before o 
chemotherapy.
No elective dental treatment should be 
carried out.
ONLY emergency dental care.
Elective dental treatment.−	
 NSAID: nonsteroidal antiinflammatory drugs.
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the planned treatment (particularly surgical treatment), 
in case it is possible to postpone therapy until wound 
healing has been achieved (4-6 weeks are recommen-
ded)(23,36). Two independent studies have shown that 
opportune dental detection and preventive treatment 
significantly reduce the risk of ONJ versus the controls 
(6.7% versus 26.3%, and 3.2% versus 1.3%, respecti-
vely)(37,38). If surgery proves necessary, prior infor-
med consent is to be obtained, and the operation should 
be minimally traumatic in order to secure good and rapid 
Fig. 2. Algorithm: dental treatment before, during and after chemotherapy in patients treated with intravenous bisphosphonates. BPs: bisphos-
phonates; ONJ: osteonecrosis of the jaw; CLX: chlorhexidine.
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healing. 
Treatment during chemotherapy
The oncologist is to be consulted in order to know the 
degree of immune suppression of the patient. Continued 
patient reminder of the need to maintain strict dental hy-
giene is indicated, with the added use of chlorhexidine 
rinses and fluorization.
During this period, the previously mentioned complica-
tions of chemotherapy are to be treated (mucositis, xe-
rostomia, etc.). No elective dental treatment should be 
carried out (Table 4), and intervention is to be limited 
to infectious processes and pain (i.e., emergency dental 
care).
In these cases, great caution is required with the admi-
nistration of drugs, since all antineoplastic agents cau-
se bone marrow suppression to one degree or other, as 
well as variable liver toxicity, nephrotoxicity, ototoxici-
ty and gastrointestinal disorders. It is preferable to use 
paracetamol or metamizol, due to the interactions that 
occur between nonsteroidal antiinflammatory drugs and 
immunosuppressors (with corticosteroids: risk of gas-
tric ulcer; with cyclosporine: nephrotoxicity; with me-
thotrexate: risk of bleeding). For the administration of 
antibiotics, and in the case of kidney problems, dose ad-
justment is required according to the observed creatinine 
clearance values.
If the patient is receiving treatment with intravenous 
BPs
There are no contraindications to conservative dental 
treatment in patients receiving intravenous BPs (36-38). 
In this context, tartar removal can be carried out, with a 
view to eliminating this source of mechanical and biolo-
gical irritation. Removable dentures are not contraindi-
cated, though the dentist must be particularly carefully 
to avoid the development of friction ulcers, and any such 
lesions must be treated as soon as possible (24,31,32,39). 
If such ulcers appear, the dentures must be removed, fo-
llowed by patient control after 7-10 days. During this pe-
riod, it is advisable for the dentist to examine the patient 
every 6 months (23).
Scaling and root planing are only advised where strictly 
necessary in order to avoid irritation of the alveolar bone 
and overlying mucosa. Periodontal treatment with flap 
raising is not indicated, since it requires bone exposure, 
with the consequent risk of ONJ (Fig. 2).
Whenever possible, tooth extractions are to be avoided, 
with conservative management of those lesions that ex-
ceed the amelodentinal limit (24,32). If extraction proves 
necessary, the recommendations of the Spanish expert 
committee should be followed (23): before any surgical 
intervention, the patient is to be carefully informed of 
the risks of ONJ, with signing of the corresponding con-
sent document. Different authors recommend the sus-
pension of BP therapy, though there is no evidence that 
such suspension prevents the development of ONJ, since 
the half-life of bisphosphonates is extremely long (39). 
Tooth extraction should be minimally traumatic, with 
curettage of the socket, cleansing of the surgical bed and 
suturing of the wound margins. Antibiotic prophylaxis is 
to be provided before and after extraction.
Regarding dental implant placement in these patients, 
the available data are very limited, though all the stu-
dies found in the literature speak against such treatment 
(24,32,39-41).
Orthodontic treatment in these patients is not recommen-
ded, due to the seriousness of their background illness, 
and due to the important osteoclastic inhibition induced 
by bisphosphonate therapy, which limits or impedes 
the bone reabsorption required for dental displacement 
(41). 
Treatment after chemotherapy
Provided immune competence has been restored, and af-
ter consulting the oncologist, elective treatment may be 
provided, designed to restore or achieve good esthetic 
results and adequate function. The presence of infectious 
foci moreover should be minimized. The usual protocols 
for the management of odontogenic infections are appli-
cable in such cases (Table 4). It is also important to insist 
on the need for routine systematic oral hygiene in order 
to reduce the incidence and severity of the oral sequelae 
of antineoplastic therapy.
If the patient has received treatment with intravenous 
BPs
In those patients who have received treatment with in-
travenous BPs, the considerations for dental care are the 
same as in patients receiving treatment with intravenous 
BPs, since the half-life of these drugs ranges from 1-10 
years. When placing dental implants, it must be taken 
into account that a series of metabolic changes take pla-
ce around the implant, leading to the formation of bone 
intimately bound to the implant surface (osseointegra-
tion)(40). If the surrounding bone contains medium to 
high levels of BPs, such bone turnover and remodeling 
is hindered or prevented, with a high probability of ne-
crosis developing in the surrounding bone. The situation 
is different when patients who start to receive treatment 
with BPs already have dental implants (Fig. 2).
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